Avaliação da resposta imune de neonatos não infectados pelo HIV-1 nascidos de gestantes soropositivas

A síndrome da imunodeficiência adquirida (AIDS), causada pelo vírus da imunodeficiência humana (HIV), é uma das mais destrutivas epidemias do mundo, e a infecção pelo HIV em mulheres jovens vem aumentando rapidamente nos dias atuais. Esse fato tem um impacto importante na transmissão vertical do vírus. Apesar da grande maioria dos casos de aids pediátrica em todo mundo resultar da transmissão vertical, aproximadamente dois terços das crianças expostas ao HIV durante a vida fetal não são infectadas pelo vírus. Muitos trabalhos sugerem que durante a gestação doenças infecciosas maternas podem ter consequências complexas para o desenvolvimento do feto, e poucos trabalhos têm explorado o impacto da exposição ao HIV sobre a responsividade imunológica de crianças não infectadas a diferentes estímulos, particularmente na era das drogas antirretrovirais. Portanto, esse trabalho teve como objetivo avaliar eventos imunes em neonatos não-infectados expostos ao HIV-1 nascidos de gestantes que controlam (G1) ou não (G2) a carga viral plasmática, usando neonatos não expostos como controle. Para tanto, sangue do cordão umbilical de cada neonato foi coletado, plasma e células mononucleares foram separados e a linfoproliferação e o perfil de citocinas foram avaliados. Os resultados demonstraram que a linfoproliferação in vitro induzido por ativadores policlonais foi maior nos neonatos do G2. Entretanto, nenhuma cultura de célula respondeu a um conjunto de peptídeos sintéticos do envelope do HIV-1. A dosagem de citocinas no plasma e nos sobrenadantes das culturas ativadas policlonalmente demonstrou que, enquanto a IL-4 e IL-10 foram as citocinas dominantes produzidas nos grupos G1 e controle, a secreção de IFN-γ, IL-11538;, Il-6, IL-17 e TNF-α foi significativamente superior nos neonatos G2. Níveis sistêmicos de IL-10 observados dentre os neonatos G1 foram maiores naqueles nascidos de mães tratadas com drogas inibidoras da transcriptase reversa do vírus. Por outro lado, níveis superiores de citocinas inflamatórias foram observados dentre estes nascidos de gestantes tratadas com terapia antirretroviral de alta eficácia. Em resumo, nossos resultados indicam uma responsividade imune alterada em neonatos expostos in utero ao HIV-1 e reforça o papel do tratamento materno anti-viral com drogas menos potentes em atenuar tais distúrbios.

A novel fusion gene, TRIMS-Cyclophilin A in the pig-tailed macaque determines its susceptibility to HIV-1 infection

Objective: In Old World monkeys, the tripartite motif Sec (TRIM5 alpha) protein confers resistance to HIV-1 infection following virus entry into host cells. However, the pig-tailed macaque (Macaca nemestrina) is an exception and is susceptible to HIV-1 in

Rapid detection of white spot syndrome virus (WSSV) of Penaeus monodon by latex agglutination test using monoclonal antibodies

Latex beads were sensitized with monoclonal antibodies (MAb) rose against VP28 of WSSV. The optimum concentration of MAb required to sensitize the latex beads was 125 µg/ml. The sensitized latex beads were used to detect WSSV from PCR-positive stomach tissue homogenates obtained from infected shrimp. Stomach tissue homogenates from WSSV-infected shrimp agglutinated the sensitized latex beads within 10 minutes, while uninfected samples did not produce any agglutination, although non-specific agglutinations were observed in some samples. The analytical sensitivity, analytical specificity, diagnostic sensitivity and diagnostic specificity of the (LAT) agglutination test were assessed. The analytical sensitivity of the test was 40 ng of purified WSSV (2 µg/ml). The sensitized latex beads did not agglutinate with normal shrimp tissue or MBV-infected tissue homogenate. The test has a diagnostic sensitivity of 70 and 45%, respectively, compared to single-step and nested PCR. The diagnostic specificity of the test was 82%. This test is a simple and rapid on-farm test which can be used to corroborate clinical signs for the detection of WSSV in grow-out ponds.

树突状细胞与 HIV-1 辅助蛋白相互作用的体外研究——细胞系模型研究价值的验证和新的研究方向的确立

树突状细胞（Dendritic cells，DCs）作为人类免疫缺陷病毒（Human Immunodeficiency Virus，HIV）感染的第一靶细胞和第一道防线， 在HIV-1感染 和传播过程当中发挥重要的功能。DC的免疫功能主要包括抗原的捕获、加工、 递呈并激活T细胞对HIV-1作出免疫反应，这些功能的发挥依赖于其自身接受刺 激有效地分化和成熟。 与其它慢病毒（lentivirus）相同，HIV-1所具有的6种辅助蛋白（Nef，Rev， Tat，Vif，Vpr和Vpu），决定着病毒自身的复制增殖和对机体的感染和致病力。 目前，HIV-1辅助蛋白对CD4+ T细胞影响的研究较为深入，是否影响和调节DC 的分化和成熟尚不够清楚，现有的文献报道很少，且相互不一致甚至矛盾。因此， 建立合适的体外研究体系和细胞模型，有针对性地进行研究DC与HIV-1之间的相 互作用，将有助于加深对HIV/AIDS致病和发病机理的理解，具有重要的生物医 学意义。 本实验选择了可被HIV-1感染的白血病细胞系THP-1为实验模型，首先评价 了THP-1作为DC前体在研究DC分化、成熟中的可用性，特别是判定DC分化成熟 和功能状态的主要细胞表面标记的动态变化和规律。进而在相同条件下分析了6 个辅助蛋白基因对THP-1的凋亡诱导作用，证实了Nef和Tat确可诱导转染细胞自 身凋亡，而Rev和Vpr可在THP-1细胞中持续表达，形成了稳定的细胞系，为进一 步研究和比较Rev、Vpr对DC的分化、成熟的影响奠定了实验基础。更重要的是， 我们发现，Vif和Vpu不能在THP-1中有效表达，其原因可能直接与限制性因子 APOBEC3G的存在有关，提示Vpu与APOBEC3G可能存在着新的相互作用——这 一线索已作为实验室新的研究方向，进一步深入的研究可能为HIV/AIDS致病、 发病机理和机体的抗病机制提供新的科学依据。

平顶猴TRIM5α基因变异影响其抗HIV-1功能

目的:解释平顶猴成为唯一能够被HIV-1感染的旧大陆猴以及在被SIV感染时出现较其他旧大陆猴严重临床症状的原因.方法:参考人TRIM5α基因的结构和序列合成引物,以平顶猴DNA 为模板,分别扩增其TRIM5α基因编码序列的所有外显子.利用生物学软件分析获得的编码序列,分析在已经明确与TRIM5α抗病毒功能密切相关的几个位点上是否发生可能影响其功能的突变.结果:在平顶猴基因组上CypA基因融合到TRIM5α基因第八外显子的下游,融合方式与在鹰猴中发现的CypA与TRIM5α的融合方式完全不同.恒河猴TRIM5α基因具有限制HIV-1复制的功能,第332位脯氨酸对其抗病毒功能非常重要,但在平顶猴的TRIM5α上,该氨基酸突变成谷氨酰胺;第335位以后8个氨基酸对恒河猴TRIM5α抗病毒功能也有重要影响,但在平顶猴的TRIM5α上,与其对应的氨基酸片段不仅缺失了两个氨基酸,还有两个氨基酸发生突变,附近区域还有另外两个发生突变.在平顶猴TRIM5α基因的Coiled-Coil结构域插入了13个氨基酸,但没有影响到编码框.结论:在平顶猴的基因组上CypA与TRIM5α的融合以及平顶猴TRIM5α基因抗病毒功能关键位点上的氨基酸突变可能影响其抗病毒功能,是其成为唯一能够被HIV-1感染的旧大陆猴以及在被SIV感染时出现较其他旧大陆猴严重临床症状的重要原因.

顶体反应抑制剂4'- 乙酰胺苯基4-胍基苯甲酸酯(AGB)具有阻断HIV-1进入细胞的作用

】目的: 研究4'- 乙酰胺苯基4- 胍基苯甲酸酯(AGB)抗 HIV-1 活性及作用靶点。方法: 通过 AGB对宿主细胞的毒性实验、合胞体抑制实验、融合阻断实验、对HIV-1感染细胞的保护作用实 验和对HIV-1急性感染细胞p24抗原产生的抑制作用等试验，观察AGB对HIV-1复制的影响和作 关键词: AGB; HIV-1; 病毒进入; 杀微生物剂; 杀精子活性 中图分类号: R967; 文献标识码: A 文章编号: 0253-357X(2005)11-0660-05 本研究为国家高技术研究发展计划(2003AA219142)、国 家科技攻关计划 (2004BA719A14)、中国科学院知识创新 工程重要方向(KSCX2-SW-216; KSCX12-SW-11)、云南 省科技攻关计划(2004NG12)和云南省生育调节与少数民 族优生研究重点实验室资助项目 通讯作者: 郑永唐; Tel: +86-871-5195684; Fax:+86-871-5191823; E-mail: zhengyt@mail.kiz.ac.cn 在我国, 人免疫缺陷病毒(human immunodeficiency virus, HIV)危害日趋严重，处在全国低流行 与局部地区及特定人群高流行并存的态势。卫生部 的数据显示，截止2005 年3 月底，全国累计报告 HIV 感染者114 703 例。专家估计我国实际HIV 感 染者超过100 万人。预计到2010 年, 全国HIV感染 者将突破千万。截止2004 年底, 云南省累计报告的 HIV 感染者已达28 391 人, 是全国流行最严重的地 区。艾滋病流行正由高危人群向一般人群传播。 新的证据显示近年来由性传播途径感染的比例有所 上升, 女性感染者的比例有较大幅度的上升, 迫切需 要发展一种女性可自主控制的方法 [1]。杀微生物剂 是可以局部用药于阴道和宫颈、能够杀灭或抑制 包括HIV等病毒性和细菌性病原体、人工合成或天 然的药物。具有避孕作用的杀微生物剂更是近年 来的研究热点，也具有广阔的应用前景[2,3]。 顶体酶是存在于精子顶体内的一种类胰蛋白 酶, 它是受精过程中的一种重要的蛋白水解酶, 此酶 能水解卵细胞的透明带, 使精子能够与卵细胞相融 合; 顶体酶还能促进生殖系统中激肽的释放, 后者能 够增强精子的活力和促进精子的运动, 顶体酶的失 活将导致不孕[4]。AGB(4'- 乙酰胺苯基 4- 胍基苯甲 酸酯)是顶体酶的抑制剂, 实验表明在多种动物中有 很好的杀精子作用[5-7]。Bourimbaiar等[8]曾报道AGB 还具有体外抗HIV-1的作用, 活性较N-9高, 且毒性 较小。在本实验中, 我们发现AGB 的体外抗HIV-1 活性主要是阻断HIV-1 进入细胞。 用机制。结果: AGB抑制HIV-1IIIB诱导C8166细胞形成合胞体, EC50为39.5 μg/ml; 抑制HIV-1感染 细胞上清中HIV-1 p24抗原的表达, EC50为33.36 μg/ml; 阻断HIV-1慢性感染H9细胞与正常C8166 细胞间融合的作用。结论: AGB具有阻断HIV-1 进入宿主细胞的作用，是一种有前景的具杀精子 作用的杀微生物剂。

Anti-HIV-1 activity of trichobitacin, a novel ribosome-inactivating protein

AIM: To determine whether trichobitacin, a novel ribosome-inactivating protein purified from the root tubers of Trichosanthes kirilowii, possesses the anti-HIV activity. METHODS: The inhibition of syncytial cell formation induced by human immunodeficiency virus type 1 (HIV-1),was determined under microscope, reduction of HIV-1 p24 antigen expression level was measured by ELISA, and decrease in numbers of HIV-1 antigen positive cells in acutely and-chronically infected cultures were detected by indirect immunofluorescence assay. RESULTS: Trichobitacin Was-found to greatly suppress syncytial cell formation induced by HIV-1 and to markedly reduce both expression of HIV-1 p24 antigen and the number of HIV antigen positive cells in acutely but not chronically HIV-1 infected culture. The median inhibitory concentration (IC50) in inhibition of syncytial cell formation and HIV antigen positive cells were 5 mu g.L-1 (95 % confidence limits: 1.3 - 20 mu g.L-1) and 0.09 mg.L-1 (95 % confidence limits: 0.011 - 0.755 mg.L-1), respectively. CONCLUSION: Trichobitacin is a novel ribosome-inactivating protein with anti-HIV-l activity.

Anti-HIV-1 property of trichosanthin correlates with its ribosome inactivating activity

Trichosanthin (TCS) is a type I ribosome inactivating (RI) protein possessing anti-tumor and antiviral activity, including human immunodeficiency virus (HIV). The mechanism of these actions is not entirely clear, but is generally attributed to its RI property. In order to study the relationship between the anti-HIV-1 activity of TCS and its RI activity, three TCS mutants with different RI activities were constructed by using site-directed mutagenesis. The anti-HIV-1 activities of the three mutants were tested in vitro. Results showed that two TCS mutants, namely TCSM((120-123)), TCSE160A/E189A, with the greatest decrease in RI activity, lost almost all of the anti-HIV activity and cytopathic effect. Another mutant TCSR122G, which exhibited a 160-fold decrease in RI activity, retained some anti-HIV activity. The results from this study suggested that RI activity of TCS may have significant contribution to its anti-HIV-1 property. (C) 2002 Published by Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.

Independency of anti-HIV-1 activity from ribosome-inactivating activity of trichosanthin

Trichosanthin (TCS) is a type I ribosome-inactivating (RI) protein possessing multiple biological and pharmacological activities. Its major action is inhibition of human immunodeficiency virus (HIV) replication but the mechanism is still elusive. All evidences showed that this action is related to its RI activity. Previous studies found that TCS mutants with reduced RI activity simultaneously lost some anti-HIV activity. In this study, an exception was demonstrated by two TCS mutants retaining almost all RI activity but were devoid of anti-HIV-1 activity. Five mutants were constructed by using site-directed mutagenesis with either deletion or addition of amino acids to the C-terminal sequence. Results showed that the RI activity of mutants with C-terminal deletion mutants (TCSC2, TCSC4, and TCSC14) decreased by 1.2-3.3-fold with parallel downshifting of its anti-HIV-1 activity (1.4-4.8-fold). Another two mutants, TCSC19aa and TCSKDEL having 19 amino acid extension and a KDEL signal sequence added to the C-terminal sequence, retained all RI activity but subsequently lost most of the anti-HIV-1 activity. These findings suggested that ribosome inactivation alone might not be adequate to explain the anti-HIV action of TCS. (C) 2003 Elsevier Science (USA). All rights reserved.

Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro

Aim: To study the pharmacokinetics of sifuvirtide, a novel anti-human immunodeficiency virus (HIV) peptide, in monkeys and to compare the inhibitory concentrations of sifuvirtide and enfuvirtide on HIV-1-infected-cell fusion. Methods: Monkeys received 1.2 mg/kg iv or sc of sifuvirtide. An on-line solid-phase extraction procedure combined with liquid chromatography tandem mass spectrometry (SPELC/MS/MS) was established and applied to determine the concentration of sifuvirtide in monkey plasma. A four-I-127 iodinated peptide was used as an internal standard. Fifty percent inhibitory concentration (IC50) of sifuvirtide on cell fusion was determined by co-cultivation assay. Results: The assay was validated with good precision and accuracy. The calibration curve for sifuvirtide in plasma was linear over a range of 4.88-5000 mu g/L, with correlation coefficients above 0.9923. After iv or sc administration, the observed peak concentrations of sifuvirtide were 10626 +/- 2886 mu g/L and 528 +/- 191 mu g/L, and the terminal elimination half-lives (T,12) were 6.3 +/- 0.9 h and 5.5 +/- 1.0 h, respectively. After sc, T-max was 0.25-2 h, and the absolute bioavailability was 49% +/- 13%. Sifuvirtide inhibited the syncytium formation between HIV-1 chronically infected cells and uninfected cells with an IC50 of 0.33 mu g/L. Conclusion: An on-line SPE-LC/MS/MS approach was established for peptide pharmacokinetic studies. Sifuvirtide was rapidly absorbed subcutaneously into the blood circulation. The T-1/2 of sifuvirtide was remarkably longer than that of its analog, enfuvirtide, reported in healthy monkeys and it conferred a long-term plasma concentration level which was higher than its IC50 in vitro.

The anti-HIV-1 effect of scutellarin

Scutellarin was purified from the plant Erigeron breuiscapus (Vant.) Hand.-Mazz. The activity against 3 strains of human immunodeficiency virus (HIV) was determined in vitro in this study. These were laboratory-derived virus (HIV-I-IIIB), drug-resistant virus (HIV-I-74V), and low-passage clinical isolated virus (HIV-1(KM018)). From syncytia inhibition study, the EC50 of scutellarin against HIV-I-IIB direct infection in C8166 cells was 26 mu M with a therapeutic index of 36. When the mode of infection changed from acute infection to cell-to-cell infection, this compound became even more potent and the EC50 reduced to 15 mu M. This suggested that cell fusion might be affected by this compound. By comparing the inhibitory effects on p24 antigen, scutellarin was also found to be active against HIV-1(74V) (EC50 253 mu M) and HIV-1(KM018) (EC50 136 mu M) infection with significant difference in potency. The mechanism of its action was also explored in this study. At a concentration of 433 mu M, scutellarin inhibited 48% of the cell free recombinant HIV-1 RT activity. It also caused 82% inhibition of HIV-1 particle attachment and 45% inhibition of fusion at the concentrations of 54 mu M. In summary, scutellarin was found to inhibit several strains of HIV-1 replication with different potencies. It appeared to inhibit HIV-1 RT activity, HIV-1 particle attachment and cell fusion. These are essential activities for viral transmission and replication. (c) 2005 Elsevier Inc. All rights reserved.

An inhibitor of c-Jun N-terminal kinases (CEP-11004) counteracts the anti-HIV-1 action of trichosanthin

Trichosanthin (TCS) is a type I ribosome-inactivating protein possessing multiple biological and pharmacological activities. One of its major actions is inhibition of human immunodeficiency virus (HIV) replication. The mechanism is still not clear. It is

Synthesis and HIV-1 integrase inhibition activity of some N-arylindoles

Eight simple N-arylindoles were designed, synthesized and evaluated as human immunodeficiency virus (HIV)-1 integrase inhibitors in vitro for the first time. Among these compounds, 3b, 3e and 3g demonstrated significant anti-HIV-1 integrase activity. Espe